Related Experiment Video
Updated: Jul 5, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant
Dainius Characiejus1, Vita Pasukoniene, Renata Jonusauskaite
1Institute of Oncology, Vilnius University, Vilnius, Lithuania. dainius@banga.lt
Background:
The objective of this study was to evaluate the significance of CD8highCD57+ lymphocytes for the survival of high risk melanoma patients treated with adjuvant interferon-alpha (IFN-alpha).
Patients And Methods:
The prognostic significance of peripheral blood CD8highCD57+ lymphocyte levels for survival was analysed retrospectively in 16 IFN-alpha-treated melanoma patients with resected regional lymph node metastases. The survival of the patients was analyzed using the Kaplan-Meier method. The difference between survival curves was determined using the log-rank test.
Results:
The median survival time of patients with >23% CD8highCD57+ lymphocytes prior to treatment with IFN-alpha was 14.2 months, whereas the median survival time of patients with < 23% CD8highCD57+ lymphocytes was not reached at the time of analysis (median follow-up 24.6 months).
Conclusion:
Larger prospective studies are justified to investigate the precise value of CD8highCD57+ lymphocytes in the selection of melanoma patients for adjuvant treatment with IFN-alpha.
